Filing Details
- Accession Number:
- 0001209191-18-023850
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-04-04 17:39:50
- Reporting Period:
- 2018-04-02
- Accepted Time:
- 2018-04-04 17:39:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1636133 | J. Kurt Andrews | 1 Cedar Brook Drive, C/O Amicus Therapeutics, Inc. Cranbury NJ 08512 | Svp, Human Resources | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-04-02 | 5,000 | $6.13 | 45,469 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-04-02 | 5,000 | $14.27 | 40,469 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Disposition | 2018-04-02 | 5,000 | $0.00 | 5,000 | $6.13 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 60,000 | 2026-02-01 | No | 4 | M | Direct |
Footnotes
- The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.76. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on February 1, 2017. The remaining options began to vest and become exercisable in a series of thirty-five successive equal monthly installments on March 1, 2017, with the final installment vesting on February 1, 2020.
Billionaire Hedge Funds
